Are azole fungicides a teratogenic risk for human conceptus?

Toxicology Letters

Volumn 198, Issue 2, 2010, Pages 106-111

  Giavini, E ^a   Menegola, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Azole fungicides; Azoles; Birth defects; Fungicides; Mechanisms; Pregnancy

Indexed keywords

ECONAZOLE; ENILCONAZOLE; FLUCONAZOLE; FLUSILAZOLE; FUNGICIDE; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; PYRROLE; TRIADIMEFON; TRIADIMENOL;

AUDITORY OSSICLE; CLEFT PALATE; COCCIDIOIDES IMMITIS; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DOSE RESPONSE; DRUG WITHDRAWAL; FETUS; FUNGAL MENINGITIS; GESTATIONAL AGE; HUMAN; HUMERUS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SKELETON MALFORMATION; SKULL; SYNOSTOSIS; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTIFUNGAL AGENTS; EMBRYONIC DEVELOPMENT; FEMALE; HUMANS; IMIDAZOLES; PREGNANCY; TERATOGENS; TRETINOIN; TRIAZOLES;

ANIMALIA;

EID: 77955920494     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.07.005     Document Type: Review

References (76)

1. Abu-Abed S., MacLean G., Fraulob V., et al. Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine embryogenesis. Mech. Dev. 2002, 110:173-177.
2. Adachi I., Tachibana K., Asakura Y., et al. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene in two patients with Antley-Bixler syndrome. Am. J. Med. Genet. A 2004, 128A:333-339.
3. Aleck K.A., Bartley D.L. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am. J. Med. Gen. 1997, 72:253-256.
4. Amaral V.C.S., Nunes G.P. Ketoconazole and xuconazole-induced embryotoxicity and skeletal anomalies in Wistar rats: a comparative study. Braz. Arch. Biol. Technol. 2008, 51:1153-1161.
5. Amaral V.C.S., Nunes G.P. Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses. Arch. Toxicol. 2009, 83:863-871.
6. Bar-Oz B., Moretti M.E., Bishai R., et al. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am. J. Obstet. Gynecol. 2000, 183:617-620.
7. Berg D., Regel E., Harenberg H.E., Plempel L. Bifonazole and Clotrimazole. Their mode of action and the possible reason for the fungicidal behavior of bifonazole. Arzneimittelforsch 1984, 34:139-146.
8. Blum R.A., Wilson J.H., Hilligoss D.M., et al. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 1991, 49:420-425.
9. Boobis A.R., Ossendorp B.C., Banasiak U., et al. Cumulative risk assessment of pesticide residues in food. Toxicol. Lett. 2008, 180:137-150.
10. Carey L.C., Martinez L., Balken E., et al. Determination of human teratogeneicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res. A Clin. Mol. Teratol. 2009, 85:63-68.
11. Carter T.C., Druschel C.M., Romitti P.A., et al. Antifungal drugs and the risk of selected birth defects. Am. J. Obstet. Gynecol. 2008, 198. 191e1-191e7.
12. Choudary D., Jansson I., Schenkman J.B., et al. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. 2003, 414:91-100.
13. Colburn D.E., Giles F.J., Oladovich D., et al. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and capsofungin. Hematology 2004, 9:217-221.
14. Czeizel A.E., Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynaecol. 1998, 105:322-327.
15. Czeizel A.E., Kazy Z., Vargha P. A population-based case-control teratological study of vaginal econazole treatment during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003, 111:135-140.
16. Czeizel A.E., Kazy Z., Puhò E. Population-based case-control teratologic study of topical miconazole. Congenit. Anom. 2004, 44:41-45.
17. De Roos K., Sonneveld E., Compaan B., et al. Expression of retinoic acid 4-hydroxylase (CYP26) during mouse and Xenopus laevis development. Mech. Dev. 1999, 82:205-211.
18. De Santis M., Di Giannantonio E., Cesari E., et al. First-trimester Itraconazole exposure and pregnancy outcome. A prospective cohort study of women contacting teratology information services in Italy. Drug Saf. 2009, 32:239-244.
19. Di Renzo F., Broccia M.L., Giavini E., et al. Antifungal triazole derivative triadimefon induces ectopic maxillary cartilage by altering the morphogenesis of the first branchial arch. Birth Defects Res. B Dev. Reprod. Toxicol. 2006, 80:2-11.
20. Di Renzo F., Broccia M.L., Giavini E., et al. Citral, an inhibitor of retinoic acid synthesis, attenuates the frequency and severity of branchial arch abnormalities induced by triazole-derivative fluconazole in rat embryos cultured in vitro. Reprod. Toxicol. 2007, 24:326-332.
21. Di Renzo F., Corsini E., Broccia M.L., et al. Molecular mechamism of teratogenic effects induced by the fungicide triadimefon: study of the expression of TGF-β mRNA and TGF-β and CRABP proteins during rat in vitro development. Toxicol. Appl. Pharmacol. 2009, 234:107-116.
22. Farag A.T., Ibrahim H.H. Developmental toxic effects of antifungal flusilazole administered by gavage to mice. Birth Defects Res. B Dev. Reprod. Toxicol. 2007, 80:12-17.
23. Fluck C.E., Tajima T., Pandley A.V., et al. Mutant P459 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 2004, 36:228-230.
24. Fujii H., Sato T., Kaneko S., et al. Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. EMBO J. 1997, 16:4163-4173.
25. Giavini E., Broccia M.L., Prati M. Teratogenicity testing in vitro: post-implantation whole embryo culture. Alt. Lab. Anim. 1991, 19:94-98.
26. Giknis M.L.A., Damjanov I. The transplacental effects of ethanol and metronidazole in Swiss Webster mice. Toxicol. Lett. 1983, 19:37-42.
27. Groppelli S., Pennati R., De Bernardi F., et al. Teratogenic effects of two antifungal triazoles, triadimefon and triadimenol, on Xenopus laevis development: craniofacial defects. Aquat. Toxicol. 2005, 73:370-381.
28. Jeu L., Piacenti F.J., Lyakhoteskij A.G., Fung H.B. Voriconazole. Clin. Ther. 2003, 25:1321-1381.
29. Jick S.S. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999, 19:221-222.
30. Juchau M.R., Boutelet-Bochan H., Huang Y. Cytochrome-P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues. Drug Metab. Rev. 1998, 30:541-568.
31. Kale P., Johnson L.B. Second-generation azole antifungal agents. Drugs Today 2005, 41:91-105.
32. Kantola T., Backman J.T., Niemi M., et al. Effect of fluconazole on plasma fluvostatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 2000, 56:225-229.
33. Kazy Z., Puhò E., Czeizel A.E. Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit. Anom. 2005, 45:5-8.
34. Kazy Z., Puhò E., Czeizel A.E. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 123:174-178.
35. Kazy Z., Puhò E., Czeizel A.E. The possible association between the combination of vaginal metronidazole and miconazole treatment and poly-syndactily. Population based case-control teratologic study. Reprod. Toxicol. 2005, 20:89-94.
36. Kelley R.I., Roessler E., Hennekam R.C.M., et al. Holoprosencephaly in RSH/Smith-Lemli-Opitz syndrome: does abnormal cholesterol metabolism affect the function of Sonic Hedgehog?. Am. J. Med. Genet. 1996, 66:478-484.
37. Kessel M., Gruss P. Homeotic transformations of murine vertebrae and concomitant alteration of Hox codes induced by retinoic acid. Cell 1991, 67:89-104.
38. King C.T., Rogers P.D., Cleary J.D., Chapman S.W. Antifungal therapy during pregnancy. Clin. Infect. Dis. 1998, 27:1151-1160.
39. Kolf-Clauw M., Chevy F., Siliart B., et al. Cholesterol biosynthesis inhibited by BM15.766 induces holoprosencephaly in the rat. Teratology 1997, 56:188-200.
40. Lee B.E., Feinberg M., Abraham J.J., et al. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr. Infect. Dis. J. 1992, 11:1062-1064.
41. Lopez-Rangel E., Van Allen M.I. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res. A Clin. Mol. Teratol. 2005, 73:919-923.
42. Machera K. Developmental toxicity of Cyproconazole, an inhibitor of fungal ergosterol biosynthesis, in the rat. Bull. Environ. Contam. Toxicol. 1995, 54:363-369.
43. Massa V., Gaudenzi G., Sangiorgio L., et al. Krox20 is down regulated following triazole in vitro embryonic exposure: a polycompetitor-based assay. Toxic. Lett. 2007, 169:196-204.
44. Mastroiacovo P., Mazzone T., Botto L.D., et al. Prospective assessment of pregnancy outcomes after first trimester exposure to fluconazole. Am. J. Obstet. Gynecol. 1996, 175:1645-1650.
45. Menegola E., Broccia M.L., Di Renzo F., et al. In vitro teratogenic potential of two antifungal triazoles: triadimefon and triadimenol. In Vitro Cell. Dev. Biol. 2000, 36:88-95.
46. Menegola E., Broccia M.L., Di Renzo F., et al. Antifungal triazoles induce malformations in vitro. Reprod. Toxicol. 2001, 15:421-427.
47. Menegola E., Broccia M.L., Di Renzo F., et al. Pathogenic pathways in fluconazole-induced branchial arch malformations. Birth Defects Res. A Clin. Mol. Teratol. 2003, 67:116-124.
48. Menegola E., Broccia M.L., Di Renzo F., et al. Relationship between hindbrain segmentation, neural crest cell migration and branchial arch abnormalities in rat embryos exposed to fluconazole and retinoic acid in vitro. Reprod. Toxicol. 2004, 18:121-130.
49. Menegola E., Broccia Ml, Di Renzo F., et al. Study of the common teratogenic pathway elicited by the fungicides triazole-derivatives. Toxicol. In Vitro 2005, 19:737-748.
50. Menegola E., Broccia M.L., Di Renzo F., et al. Craniofacial and axial skeletal defects induced by the fungicide triadimefon in the mouse. Birth Defects Res. B Dev. Reprod. Toxicol. 2005, 74:185-195.
51. Menegola E., Broccia M.L., Di Renzo F., et al. Dysmorphogenic effects of some fungicides derived from the imidazole on rat embryos cultured in vitro. Reprod. Toxicol. 2006, 21:74-82.
52. Menegola E., Di Renzo F., Broccia M.L., et al. Cleft palate and exposure to an azole derivative: triadimefon. Reprod. Toxicol. 2009, 28:13.
53. Morris-Kay G.M. Retinoic acid and development. Pathobiology 1992, 60:264-270.
54. Morris-Kay G.M., Murphy P., Hill R.E., et al. Effects of retinoic acid excess on expression of Hox-2.9 and Krox-20 and on morphological segmentation in the hindbrain of mouse embryos. EMBO J. 1991, 10:2985-2995.
55. New D.A.T. Whole embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. 1978, 53:81-122.
56. Niwa T., Shiraga T., Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP)2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 2005, 28:1805-1808.
57. Papis E., Bernardini G., Gornati R., et al. Gene expression in Xenopus laevis embryos after triadimefon exposure. Gene Expr. Patterns 2007, 7:137-142.
58. Pennati R., Groppelli S., Zega G., et al. Toxic effects of two pesticides, imazalil and triadimefon, on the early development of the ascidian Phallusia mammillata (Chordata, Ascidiacea). Aquat. Toxicol. 2006, 79:205-212.
59. Pursley T.J., Blomquist I.K., Abraham J., et al. Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. 1996, 22:336-340.
60. Ross S.A., McCaffery P.J., Drager U.C., et al. Retinoids in embryonal development. Physiol. Rev. 2000, 80:1021-1054.
61. Roux C., Dupuis R., Horvat C., et al. Teratogenic effect of an inhibitor of cholesterol synthesis (AY9944) in rats: correlation with maternal cholesterolemia. J. Nutr. 1980, 110:2310-2312.
62. Schwartz E.L., Hallam S., Gallagher R.E., Wiernik P.H. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem. Pharmacol. 1995, 50:923-928.
63. Sheets J.J., Mason J.I. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab. Dispos. 1984, 12:603-606.
64. Sorensen H.T., Nielsen G.L., Olesen C., et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br. J. Clin. Pharmacol. 1999, 48:234-238.
65. Summerbell D., Maden M. Retinoic acid, a developmental signaling molecule. Trends Neurosci. 1990, 13:142-147.
66. Tiboni G.M. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res. Comm. Chem. Pathol. Pharmacol. 1993, 79:381-384.
67. Tiboni G.M., Iammarrone E., Giampiero F., et al. Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. Teratology 1999, 59:81-87.
68. Tiboni G.M., Giampietro F. Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence. Pediatr. Res. 2005, 58:94-99.
69. Tiboni G.M., Marotta F., Del Corso A., et al. Defining critical periods for itraconazole-induced cleft palate, limb defects and axial skeletal malformations in the mouse. Toxicol. Lett. 2006, 167:8-18.
70. Tiboni G.M., Marotta F., Castigliego A.P. Teratogenic effects in mouse fetuses subjected to the concurrent in utero exposure to miconazole and metronidazole. Reprod. Toxicol. 2008, 26:254-261.
71. Tiboni G.M., Marotta F., Carletti E. Fluconazole alters CYP26 gene expression in mouse embryos. Reprod. Toxicol. 2009, 27:199-202.
72. Van den Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr. Top. Med. Mycol. 1985, 1:313-351.
73. Vanier K.L., Mattiussi A.J., Johnston D.L. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocitic leukemia. J. Pediatr. Hematol. Oncol. 2003, 25:403-404.
74. Venkatakrishnan K, von Moltkle L.L., Greenblat D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 2000, 38:111-180.
75. Whiting J. Craniofacial abnormalities induced by the ectopic expression of homeobox genes. Mutat. Res. 1997, 396:97-112.
76. Zega G., De Bernardi F., Groppelli S., et al. Effects of the azole fungicide imazalil on the development of the ascidian Ciona intestinalis (Chordata Tunicata): morphological and molecular characterization of the induced phenotype. Aquat. Toxicol. 2009, 91:255-261.